{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T01:47:30Z","timestamp":1782870450006,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s12185-026-04180-8","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T18:34:36Z","timestamp":1771612476000},"page":"85-95","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prospective observational study to assess the prognosis of patients with myeloproliferative neoplasms in Japan (MPN-15): results of baseline analysis"],"prefix":"10.1007","volume":"124","author":[{"given":"Katsuto","family":"Takenaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Kirito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomiteru","family":"Togano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Murai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideho","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiro","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiaki","family":"Koike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Gotoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Maekawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Kubuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Akagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuji","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Edahiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinori","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki I.","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Shimoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Kada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko M.","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Kiyoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itaru","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akifumi","family":"Takaori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"issue":"2","key":"4180_CR1","doi-asserted-by":"publisher","first-page":"100397","DOI":"10.1016\/j.modpat.2023.100397","volume":"37","author":"S Loghavi","year":"2024","unstructured":"Loghavi S, Kanagal-Shamanna R, Khoury JD, Medeiros LJ, Naresh KN, Nejati R, et al. Fifth edition of the world health classification of tumors of the hematopoietic and lymphoid tissue: myeloid neoplasms. Mod Pathol. 2024;37(2):100397.","journal-title":"Mod Pathol"},{"issue":"11","key":"4180_CR2","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200\u201328.","journal-title":"Blood"},{"issue":"6","key":"4180_CR3","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","volume":"129","author":"W Vainchenker","year":"2017","unstructured":"Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017;129(6):667\u201379.","journal-title":"Blood"},{"issue":"20","key":"4180_CR4","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405.","journal-title":"Blood"},{"issue":"16","key":"4180_CR5","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","volume":"124","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124(16):2507\u201313.","journal-title":"Blood"},{"issue":"24","key":"4180_CR6","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1200\/JCO.2012.42.1925","volume":"30","author":"M Hultcrantz","year":"2012","unstructured":"Hultcrantz M, Kristinsson SY, Andersson TM, Landgren O, Eloranta S, Derolf AR, et al. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol Offi J American Soc Clin Oncol. 2012;30(24):2995\u20133001.","journal-title":"J Clin Oncol Offi J American Soc Clin Oncol"},{"issue":"3","key":"4180_CR7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1182\/blood.2024025459","volume":"145","author":"H Pasquer","year":"2025","unstructured":"Pasquer H, Kiladjian JJ, Benajiba L. Current myeloproliferative neoplasm scoring systems for clinical practice. Blood. 2025;145(3):257\u201376.","journal-title":"Blood"},{"issue":"5","key":"4180_CR8","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1532\/IJH97.06009","volume":"83","author":"K Dan","year":"2006","unstructured":"Dan K, Yamada T, Kimura Y, Usui N, Okamoto S, Sugihara T, et al. Clinical features of polycythemia vera and essential thrombocythemia in Japan: retrospective analysis of a nationwide survey by the Japanese Elderly Leukemia and Lymphoma Study Group. Int J Hematol. 2006;83(5):443\u20139.","journal-title":"Int J Hematol"},{"issue":"1","key":"4180_CR9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s12185-016-2102-3","volume":"105","author":"K Takenaka","year":"2017","unstructured":"Takenaka K, Shimoda K, Uchida N, Shimomura T, Nagafuji K, Kondo T, et al. Clinical features and outcomes of patients with primary myelofibrosis in Japan: report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan. Int J Hematol. 2017;105(1):59\u201369.","journal-title":"Int J Hematol"},{"issue":"5","key":"4180_CR10","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s12185-022-03412-x","volume":"116","author":"Y Edahiro","year":"2022","unstructured":"Edahiro Y, Ito T, Gotoh A, Nakamae M, Kimura F, Koike M, et al. Clinical characteristics of Japanese patients with polycythemia vera: results of the JSH-MPN-R18 study. Int J Hematol. 2022;116(5):696\u2013711.","journal-title":"Int J Hematol"},{"issue":"2","key":"4180_CR11","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s12185-021-03253-0","volume":"115","author":"Y Hashimoto","year":"2022","unstructured":"Hashimoto Y, Ito T, Gotoh A, Nakamae M, Kimura F, Koike M, et al. Clinical characteristics, prognostic factors, and outcomes of patients with essential thrombocythemia in Japan: the JSH-MPN-R18 study. Int J Hematol. 2022;115(2):208\u201321.","journal-title":"Int J Hematol"},{"issue":"1","key":"4180_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s12185-024-03865-2","volume":"121","author":"N Takahashi","year":"2025","unstructured":"Takahashi N, Takenaka K, Iriyama N, Kirito K, Kawaguchi T, Kimura S, et al. JSH practical guidelines for hematological malignancies, 2023: leukemia-4. Chronic myeloid leukemia (CML)\/myeloproliferative neoplasms (MPN). Int J Hematol. 2025;121(1):5\u201338.","journal-title":"Int J Hematol"},{"issue":"4","key":"4180_CR13","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1053\/j.seminhematol.2005.08.003","volume":"42","author":"A Tefferi","year":"2005","unstructured":"Tefferi A, Spivak JL. Polycythemia vera: scientific advances and current practice. Semin Hematol. 2005;42(4):206\u201320.","journal-title":"Semin Hematol"},{"issue":"3","key":"4180_CR14","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1046\/j.1365-2141.1998.01021.x","volume":"103","author":"M Ruggeri","year":"1998","unstructured":"Ruggeri M, Finazzi G, Tosetto A, Riva S, Rodeghiero F, Barbui T. No treatment for low-risk thrombocythaemia: results from a prospective study. Br J Haematol. 1998;103(3):772\u20137.","journal-title":"Br J Haematol"},{"issue":"9","key":"4180_CR15","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/leu.2013.163","volume":"27","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874\u201381.","journal-title":"Leukemia"},{"issue":"6","key":"4180_CR16","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1182\/blood-2012-01-403279","volume":"120","author":"F Passamonti","year":"2012","unstructured":"Passamonti F, Thiele J, Girodon F, Rumi E, Carobbio A, Gisslinger H, et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood. 2012;120(6):1197\u2013201.","journal-title":"Blood"},{"issue":"4","key":"4180_CR17","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","volume":"29","author":"N Gangat","year":"2011","unstructured":"Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392\u20137.","journal-title":"J Clin Oncol"},{"issue":"33","key":"4180_CR18","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","volume":"30","author":"RM Emanuel","year":"2012","unstructured":"Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30(33):4098\u2013103.","journal-title":"J Clin Oncol"},{"issue":"16","key":"4180_CR19","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1182\/blood.2022017578","volume":"141","author":"D Luque Paz","year":"2023","unstructured":"Luque Paz D, Kralovics R, Skoda RC. Genetic basis and molecular profiling in myeloproliferative neoplasms. Blood. 2023;141(16):1909\u201321.","journal-title":"Blood"},{"issue":"1","key":"4180_CR20","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1182\/asheducation-2017.1.470","volume":"2017","author":"J Nangalia","year":"2017","unstructured":"Nangalia J, Green AR. Myeloproliferative neoplasms: from origins to outcomes. Hematology. 2017;2017(1):470\u20139.","journal-title":"Hematology"},{"issue":"24","key":"4180_CR21","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.1182\/blood-2013-09-527903","volume":"123","author":"HL Geyer","year":"2014","unstructured":"Geyer HL, Scherber RM, Dueck AC, Kiladjian JJ, Xiao Z, Slot S, et al. Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. Blood. 2014;123(24):3803\u201310.","journal-title":"Blood"},{"issue":"10","key":"4180_CR22","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","volume":"123","author":"E Rumi","year":"2014","unstructured":"Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014;123(10):1544\u201351.","journal-title":"Blood"},{"issue":"7","key":"4180_CR23","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","volume":"124","author":"E Rumi","year":"2014","unstructured":"Rumi E, Pietra D, Pascutto C, Guglielmelli P, Martinez-Trillos A, Casetti I, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood. 2014;124(7):1062\u20139.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04180-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04180-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04180-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T01:08:40Z","timestamp":1782868120000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-026-04180-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["4180"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04180-8","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"assertion":[{"value":"2 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Katsuto Takenaka reports honoraria from Novartis Pharmaceutical, PharmaEssentia Japan K.K., Takeda Pharmaceutical, MSD, and GlaxoSmithKlineK.K. Tomoki Ito reports research funds under contract from Asahi Kasei Pharma and Meiji Seika Pharma; and honoraria from Novartis Pharmaceutical, Takeda Pharmaceutical, Chugai Pharmaceutical, Janssen Pharmaceutical, Bristol\u2010Myers Squibb, AbbVie G.K.., AstraZeneca K.K., Argenx Japan K.K., and BeOne Medicine. Norio Komatsu reports research funds under contract from PharmaEssentia Japan K.K.; and a board member of PharmaEssentia Japan K.K. Hiroki Yamaguchi reports honoraria from Nippon Shinyaku Pharmaceutical, PharmaEssentia Japan K.K., Novartis Pharmaceutical, Daiichi Sankyo, AbbVie G.K., Astellas Pharma, Chugai Pharmaceutical, Genmab A\/S, Sanofi K.K., Janssen Pharmaceutical, Kyowa Kirin, Alexion Pharma G.K., AstraZeneca K.K., Shionogi, and Ono Pharmaceutical; and consulting fees from Nippon Shinyaku Pharmaceutical, PharmaEssentia Japan K.K., Novartis Pharmaceutical, AbbVie G.K., Sumitomo Pharma, and Ono Pharmaceutical. Keita Kirito reports honoraria from Novartis Pharmaceutical, PharmaEssentia Japan K.K., and GlaxoSmithKline K.K. Akihiro Tomita reports honoraria from AstraZeneca K.K., Chugai Pharmaceutical, AbbVie G.K., Takeda Pharmaceutical, Nippon Zenyaku Kogyo, SymBio Pharmaceutical, Kyowa Kirin, Genmab A\/S, Eisai, Astellas Pharma, Janssen Pharmaceutical, and Bristol\u2010Myers Squibb. Yuka Sugimoto reports research funds under contract from Toyo Kohan, Incyte Biosciences Japan G.K., MSD, Sumitomo Pharma, and Sobi Japan; and honoraria from Novartis Pharmaceutical, PharmaEssentia Japan K.K., and GlaxoSmithKline K.K.; and serving on the editorial board of Japan Society of Hematology. Hideho Wada reports honoraria from Recordati Rare Diseases Japan K.K., Sanofi K.K., and Gilead Sciences. Akihiko Gotoh reports research funds under contract from Asahi Kasei Pharma, Taiho Pharmaceutical, Otsuka Pharmaceutical, Kyowa Kirin, and Chugai Pharmaceutical; and honoraria from PharmaEssentia Japan K.K., Novartis Pharma, Alexion Pharmaceuticals, Asahi Kasei Pharma, Ono Pharmaceutical, Taiho Pharmaceutical, Takeda Pharmaceutical, Nippon Shinyaku Pharmaceutical, Chugai Pharmaceutical, Otsuka Pharmaceutical, Sumitomo Pharma, Daiichi Sankyo, GlaxoSmithKline K.K., Kyowa Kirin, Janssen Pharmaceutical K.K., Pfizer Japan, and Sanofi K.K.; consulting fees from PharmaEssentia Japan K.K., Chugai Pharmaceutical, and Alexion Pharmaceuticals; and serving on advisory board for PharmaEssentia Japan K.K., Chugai Pharmaceutical, and Alexion Pharmaceuticals. Kazuhiko Ikeda reports honoraria from Novartis Pharmaceutical, PharmaEssentia Japan K.K., and GlaxoSmithKline K.K., and Takeda Pharmaceutical. Toshinori Kondo reports honoraria from Novartis Pharmaceutical, PharmaEssentia Japan K.K., GlaxoSmithKline K.K., Nippon Shinyaku Pharmaceutical, Takeda Pharmaceutical, Otsuka Pharmaceutical, and Bristol\u2010Myers Squibb. Yasushi Miyazaki reports honoraria from Novartis Pharmaceutical, Chugai Pharmaceutical, Bristol\u2010Myers Squibb, Daiichi Sankyo, AbbVie G.K., and Incyte Biosciences Japan G.K.; and serving as managing director of Japan Adult Leukemia Study Group; and serving on the editorial board of Japan Society of Hematology. Kazuya Shimoda reports research funds under contract from Incyte Biosciences Japan G.K., Sumitomo Pharma, and PharmaEssentia Japan K.K.; and honoraria from Novartis Pharmaceutical, PharmaEssentia Japan K.K., and GlaxoSmithKline K.K.; and serving on advisory board for GlaxoSmithKline K.K.,\u3000Sumitomo Pharma, and Merck. Hitoshi Kiyoi reports research funds under contract from FUJIFILM. Otsuka Pharmaceutical, Kyowa Kirin, Perseus Proteomics, Bristol-Myers Squibb, Daiichi Sankyo, AbbVie G.K., Astellas Pharma, CURED, Chugai Pharmaceutical, Nippon Zenyaku Kogyo, Eisai, Nippon Shinyaku Pharmaceutical, Takeda Pharmaceutical, and Sumitomo Pharma; and honoraria from Astellas Pharma, AbbVie G.K., and Chugai Pharmaceutical. Koichi Akashi reports research funds under contract from AbbVie G.K. and Kyowa Kirin; and honoraria from AbbVie G.K., Chugai Pharmaceutical, Bristol-Myers Squibb, Kyowa Kirin, Janssen Pharmaceutical, Nippon Shinyaku Pharmaceutical, and Asahi Kasei Pharma. Itaru Matsumura reports research funds under contract from Chugai Pharmaceutical, Asahi Kasei Pharma, Kyowa Kirin, Sumitomo Pharma, Eisai, Taiho Pharmaceutical, AbbVie G.K., and Otsuka Pharmaceutical; and honoraria from Novartis Pharmaceutical, Bristol-Myers Squibb, Chugai Pharmaceutical, Janssen Pharmaceutical, Pfizer Japan, Otsuka Pharmaceutical, AbbVie G.K., Takeda Pharmaceutical, Ono Pharmaceutical. SymBio Pharmaceutical, Sanofi K.K., Astellas Pharma, and AstraZeneca K.K.; and consulting fee from Otsuka Pharmaceutical. Akifumi Takaori reports research funds under contract from PharmaEssentia Japan K.K.; and honoraria from Novartis Pharmaceutical and Janssen Pharmaceutical; and serving on the editorial board of Japan Society of Hematology. None of the other authors have any conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}